Please login to the form below

Not currently logged in
Email:
Password:

Simbrinza

This page shows the latest Simbrinza news and features for those working in and with pharma, biotech and healthcare.

Novartis' glaucoma combo cleared in Europe

Novartis' glaucoma combo cleared in Europe

in trials Simbrinza was able to decrease it by 23-37 per cent. ... Simbrinza's EU launch will start in the UK later this quarter, followed by other European markets in the remainder of 2014 and in 2015.

Latest news

  • CHMP backs European approval for six new medicines CHMP backs European approval for six new medicines

    Finally, Novartis' eyecare subsidiary Alcon got a green light for its combination glaucoma therapy Simbrinza (brinzolamide/brimonidine - first approved in the US last year - while Veloxis Pharma got the nod for

  • Novartis lifts 2013 guidance on delay to Diovan generics Novartis lifts 2013 guidance on delay to Diovan generics

    Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis

  • FDA approves Alcon eye drug Simbrinza FDA approves Alcon eye drug Simbrinza

    FDA approves Alcon eye drug Simbrinza. Fixed-combination licensed to treat glaucoma patients in the US. ... Novartis subsidiary Alcon has been given a boost after US regulators approved its fixed-combination eye treatment Simbrinza Suspension.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics